Jackson Financial enters the post-earnings stretch with short sellers quietly rebuilding positions and options traders expressing the most defensive skew of the past year.
Short interest has climbed sharply over the past month, rising 31% to 5.1% of the free float. That rate of accumulation is the more telling detail. The week-on-week jump of 11% — from roughly 3.1 million to 3.5 million shares — is the steepest single-week move in the 30-day window. Days to cover have stretched to 6.9, per the most recent FINRA data. This is not an extreme level of short positioning by absolute measure, but the pace of rebuilding after early April lows is notable for a stock that had been relatively unbothered by bearish flows.
Options positioning is the sharpest angle this week. The put/call ratio has climbed to 1.90 — exactly the 52-week high — running nearly 1.8 standard deviations above its 20-day average of 1.51. The PCR had been rangebound near 1.1 through early April; the move higher started around May 5 and has been consistent. That points to a deliberate tilt toward downside protection rather than a one-day spike. Borrow conditions remain loose, with availability ample — cost to borrow has dropped to 0.31%, down 23% on the week and 25% over the past month. The combination tells a nuanced story: shorts are building, but not because borrows are scarce or the squeeze trade is on. The demand for puts is running well ahead of what the lending market alone would imply.
The Street is modestly constructive but not enthusiastic. Keefe, Bruyette & Woods raised its price target to $125 this week from $120, while maintaining a Market Perform rating — a positive revision that nonetheless keeps the stock in neutral territory. Barclays holds Overweight at $136. The consensus target of $123.50 implies around 13% upside from the current $109.08. Valuation looks undemanding at a P/E of 4.6x and price-to-book of 0.74x, suggesting the stock is priced cheaply in absolute terms. EPS momentum factor scores are weak — ranking in the 12th percentile on 30-day momentum and 18th on a 90-day basis — which likely explains why the multiple hasn't expanded despite the 7% one-month price gain. Forward EPS growth expectations rank in the 65th percentile, providing at least a medium-term anchor for bulls.
The institutional picture adds context. BlackRock materially added to its position, reporting an increase of 2.75 million shares through April 30 — a significant move that brought its stake to 9.5% of shares outstanding. Vanguard also added modestly in Q1. The top-ten holders collectively represent well over 40% of outstanding shares, which concentrates the float meaningfully. The recent insider activity runs in the opposite direction: CEO Laura Prieskorn sold over $9 million in stock back in March at around $108. The CFO and a director also trimmed positions around the same time. Those sales are now two months old and occurred near current price levels, limiting their immediate read-through, but the net 90-day insider value figure is a net sale of $16 million.
Peer performance adds a degree of relative comfort. Close correlates EQH and CRBG are both down more than 8% on the week, while JXN is flat-to-slightly-positive over the same period. VOYA shed 2.6%. The earnings print on May 5-6 produced a 1-day move of just 1.3% and a 5-day drawdown of 3.8%. With no next earnings event flagged, near-term catalysts are less obvious.
Overall, the positioning here looks more charged than the borrow market alone suggests — shorts rebuilding at pace, puts at a yearly high, and yet cheap valuations and a significant institutional buyer provide the countervailing weight. The stock's next move is likely to depend on whether the macro-driven put demand persists or proves transient as the insurance-sector earnings season fades.
See the live data behind this article on ORTEX.
Open JXN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
